Structure Therapeutics oral GLP-1 candidate, aleniglipron, is showing compelling Phase II results, delivering ~16% weight loss over ~44 weeks and demonstrating strong tolerability
GLP-1R populations in the nucleus accumbens (ACBs), paraventricular nucleus (PVH), lateral hypothalamus (LHA), and ventral tegmental area (VTA) are involved in food choice, reward, and taste aversion [40]
This response includes releasing insulin, slowing down digestion, and sending signals to the brain that lead to reduced hunger
This is especially important for: marathon runners Ironman athletes ultra runners long-distance cyclists Athletes using GLP-1 medications should pay extra attention to: pre-workout fueling carbohydrates during exercise post-workout recovery nutrition blood sugar monitoring Chris is also a big fan of continuous glucose monitors when they are used with the right education and support
Three ingredients receive specific attention: myHMB, berberine, and probiotics